A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Oscient Pharmaceuticals

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs.

The Company is marketing its FDA-approved lead product, FACTIVE® (gemifloxacin mesylate) tablets. In addition to the oral tablet form, Oscient Pharmaceuticals is developing a FACTIVE intravenous formulation for hospitalized patients.

The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated diarrhea (CDAD). The Company's preclinical programs include an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.




FACTIVE TABLETS (Acute Bacterial Sinusitis) FACTIVE (gemifloxacin mesylate) tablets, indicated for the treatment of community-acquired pneumonia of mild-to-moderate severity and acute bacterial exacerbations of chronic bronchitis.

Ramoplanin --treatment of Clostridium difficile-associated diarrhea (CDAD)

FACTIVE -Intravenous-- Bacterial Infections

Oral PDF (Peptide Deformylase Inhibitors) - Respiratory Tract Infections



Home Page

Key Statistics for Oscient

Basic Chart for Oscient

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.